Even with the discrepancies in the frequency of occurrence of HER2 amplifications in patients with gastric cancer, these mutations have, in addition to their previously mentioned prognostic value, a high predictive value, as it has been shown that therapy with anti-HER2 monoclonal antibodies generates good response rates in this type of patients [13,14]. This evidence concerns the gene ERBB2 and gastric cancer.